Current approaches to pharmacotherapy for smoking cessation

Therapeutic Advances in Respiratory Disease

Volumn 4, Issue 1, 2010, Pages 35-47

  Suchanek Hudmon, Karen ^a   Corelli, Robin L ^b   Prokhorov, Alexander V ^c  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

pharmacotherapy; smoking cessation; tobacco dependence

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; CLONIDINE; COMMIT; CORTICOSTEROID; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; TAR; TOBACCO SMOKE; UNCLASSIFIED DRUG; VARENICLINE;

ABNORMAL DREAMING; ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; COUGHING; COUNSELING; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DYSPEPSIA; ERYTHEMA; FLATULENCE; HEARTBURN; HICCUP; HUMAN; HYPERSALIVATION; INSOMNIA; LACRIMATION; LARYNGITIS; LUNG CANCER; MENTAL DISEASE; MORNING DOSAGE; MOUTH PAIN; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NOSE IRRITATION; PATIENT COMPLIANCE; PHARYNGITIS; PNEUMONIA; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RISK FACTOR; SEIZURE; SELF HELP; SIDE EFFECT; SINUSITIS; SKIN BURNING SENSATION; SKIN MANIFESTATION; SMOKING CESSATION; SNEEZING; THROAT IRRITATION; TOBACCO DEPENDENCE; UNITED STATES; VIVID DREAM; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; ANIMALS; BENZAZEPINES; BUPROPION; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; PREGNANCY; QUINOXALINES; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; UNITED STATES;

EID: 76349092478     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809353768     Document Type: Review

References (40)

1. American Cancer Society (2009). Cancer Facts & Figures (2009), American Cancer Society: Atlanta, GA.
2. Bars, M.P., Banauch, G.I., Appel, D., Andreachi, M., Mouren, P., Kelly, K.J. et al. (2006) Tobacco Free with FDNY: The New York City Fire Department World Trade Center Tobacco Cessation Study. Chest 129: 979-987.
3. Benowitz, N. and Dempsey, D. ( 2004) Pharmacotherapy for smoking cessation during pregnancy. Nicotine Tob Res 6(Suppl. 2): S189-202.
4. Benowitz, N.L. ( 2003) Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 46: 91-111.
5. Benowitz, N.L. ( 2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49: 57-71.
6. Benowitz, N.L., Hukkanen, J. and Jacob 3rd, P. ( 2009) Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 29-60.
7. Benowitz, N.L., Zevin, S. and Jacob, P. ( 1997) Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol 43: 259-267.
8. Cahill, K., Stead, L.F. and Lancaster, T. ( 2008) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev CD006103.
9. CDC (2008a) Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR 57: 1226-1228.
10. CDC (2008b) Cigarette smoking among adults - United States, 2007. MMWR 57: 1221-1226.
11. Coe, J.W., Brooks, P.R., Vetelino, M.G., Wirtz, M.C., Arnold, E.P., Huang, J. et al. (2005) Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477.
12. Cosio, M.G., Saetta, M. and Agusti, A. (2009) Immunologic aspects of chronic obstructuve pulmonary disease. N Engl J Med 360: 2445-2454.
13. Ebbert, J.O., Burke, V.M., Hays, J.T. and Hurt, R.D. (2009a) Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 11: 572-576.
14. Ebbert, J.O., Croghan, I.T., Sood, A., Schroeder, D.R., Hays, J.T. and Hurt, R.D. (2009b) Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 11: 234-239.
15. Fiore, M.C., Jaén, C.R., Baker, T.B., Bailey, W.C., Benowitz, N.L., Curry, S.J. et al. (2008) Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline, U.S. Department of Health and Human Services: Rockville, MD.
16. Food and Drug Administration (FDA) (2009) Information for healthcare professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm
17. Foulds, J. ( 2006) The neurobiological basis for partial agonist treatment of nicotine dependence: Varenicline. Int J Clin Pract 60: 571-576.
18. GlaxoSmithKline Inc. (2009) Zyban Package Insert. Research Triangle Park, NC.
19. GOLD (Global Initiative for Chronic Obstructive Lung Disease) (2008) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2008. Available at: http://www.goldcopd.com/
20. Gourlay, S.G., Stead, L.F. and Benowitz, N.L. ( 2004) Clonidine for smoking cessation. Cochrane Database Syst Rev CD000058.
21. Hughes, J.R., Stead, L.F. and Lancaster, T. ( 2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev CD000031.
22. Hurt, R.D., Dale, L.C., Offord, K.P., Lauger, G.G., Baskin, L.B., Lawson, G.M. et al. (1993) Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 54: 98-106.
23. Joseph, A.M. and Fu, S.S. ( 2003) Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis 45: 429-441.
24. Kamholz, S.L. ( 2004) Pulmonary and cardiovascular consequences of smoking. Med Clin North Am 88: 1415-1430.
25. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol 38: 502-509.
26. Mokdad, A.H., Marks, J.S., Stroup, D.F. and Gerberding, J.L. ( 2004) Actual causes of Death in the United States, 2000. JAMA 291: 1238-1245.
27. McRobbie, H. and Hajek, P. ( 2001) Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction 96: 1547-1551.
28. National Cancer Institute (2001) Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No. 13. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Pub. No. 02-5074: Bethesda, MD.
29. Pfizer, Inc. (2009) Chantix Package Insert. New York, NY.
30. Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P. et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
31. Slemmer, J.E., Martin, B.R. and Damaj, I.M. ( 2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327.
32. Stead, L.F., Perera, R., Bullen, C., Mant, D. and Lancaster, T. ( 2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146.
33. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 150: 447-454.
34. Tomlinson, J.E., McMahon, A.D., Chaudhuri, R., Thompson, J.M., Wood, S.F. and Thomson, N.C. ( 2005) Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 60: 282-287.
35. Transdisciplinary Tobacco Use Research Center (TTURC) Tobacco Dependence, Baker, T.B., Piper, M.E., McCarthy, D.E., Bolt, D.M., Smith, S.S., Kim, S.Y. (2007) Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res 9 (Suppl. 4): S555-70.
36. Usdhss (1994) Prventing Tobacco Use Among Young People: A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking Health.
37. Usdhhs (2004). The Health Consequences of Smoking: A Report of the Surgeon General, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Bethesda, MD.
38. World Health Organization (2008). WHO Report on the Global Tobacco Epidemic, 2008: The mPOWER Package, World Health Organization: Geneva.
39. Zhu, S., Melcer, T., Sun, J., Rosbrook, B. and Pierce, J.P. ( 2000) Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 18: 305-311.
40. Zhu, S.H., Anderson, C.M., Tedeschi, G.J., Rosbrook, B., Johnson, C.E., Byrd, M. et al. (2002) Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med 347: 1087-1093.